1. Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat.
- Author
-
Su QB, He F, Wang XD, Guan S, Xie ZY, Wang LY, Lu YJ, Gu LQ, Huang ZS, Chen X, Huang M, and Zhou SF
- Subjects
- Animals, Antineoplastic Agents administration & dosage, Cytochrome P-450 CYP1A1 metabolism, Cytochrome P-450 CYP1A2 metabolism, Cytochrome P-450 CYP3A, Diamines administration & dosage, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Injections, Intraperitoneal, Male, Microsomes, Liver metabolism, Quinolines administration & dosage, Random Allocation, Rats, Rats, Sprague-Dawley, Telomerase antagonists & inhibitors, Antineoplastic Agents pharmacokinetics, Aryl Hydrocarbon Hydroxylases metabolism, Diamines pharmacokinetics, Membrane Proteins metabolism, Quinolines pharmacokinetics
- Abstract
SYUIQ-5, a novel telomerase inhibitor, has demonstrated antitumor activity in nude mouse studies. The objective of the present study was to examine the metabolism and pharmacokinetics of SYUIQ-5 in rats. The plasma pharmacokinetics of SYUIQ-5 was nonlinear following i.p. administration at 15, 30 and 60 mg/kg. SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively. Ketoconazole significantly inhibited the metabolism of SYUIQ-5 in liver microsomes from rats pretreated with control vehicle or various inducers, whereas sulphaphenazole, ticlopidine, quinidine, and methylpyrazole had no inhibitory effects on SYUIQ-5 metabolism. Dexamethasone and beta-naphthoflavone (BNF), but not phenobarbital and ethanol, significantly induced SYUIQ-5 metabolism in rats. Alpha-naphthoflavone significantly inhibited SYUIQ-5 metabolism in liver microsomes from BNF-pretreated rats. Similar to other secondary amines, SYUIQ-5 underwent N-demethylation and O-oxygenation to at least two metabolites by rat liver microsomes. Pretreatment of rats with SYUIQ-5 at 0.1, 5 or 10 mg/kg for 5 days significantly induced the expression and activity of rat Cyp1A1/2, and induced Cyp3A1/2 expression at 10 mg/kg, but not Cyp2E1 and 2B1/2. These results indicate that that SYUIQ-5 exhibits dose-dependent pharmacokinetics in rats and it is mainly metabolized by Cyp3A1/2.
- Published
- 2008
- Full Text
- View/download PDF